Newsfeeds - Spark Newswire

1 minute read

Earnings

Vascular Biogenics Earnings Preview

Today, 5:11 PM

Vascular Biogenics (NASDAQ:VBLT) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement. Analysts estimate that Vascular Biogenics will report an earnings per share (EPS) of $-0.09.

VBLT

3 minute read

The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings

By Shanthi Rexaline

Today, 5:11 PM

Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week.

APLT

2 minute read

FDA
News

VBL Therapeutics Announces Completion Of Enrollment In Oval Phase 3 Registration-enabling Trial Of Ofra-Vec In Ovarian Cancer And Unanimous Recommendation By Independent Data Safety Monitoring Committee To Continue Study As Planned

By Benzinga Newsdesk

Today, 5:11 PM

VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today

VBLT

1 minute read

Vascular Biogenics Q3 EPS $(0.09) Beats $(0.11) Estimate, Sales $199.00K Beat $150.00K Estimate

By Bill Haddad

Today, 5:11 PM

Vascular Biogenics (NASDAQ:VBLT) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 25 percent increase over losses of $(0.12) per share from

VBLT

4 minute read

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More

By Shanthi Rexaline

Today, 5:11 PM

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.

ACRX

5 minute read

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera’s COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold

By Shanthi Rexaline

Today, 5:11 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)

ABCL

2 minute read

VBL Therapeutics Reports Independent Data Safety Monitoring Committee Provides Clearance To Continue OVAL Phase 3 Study Of VB-111 In Ovarian Cancer

By Benzinga Newsdesk

Today, 5:11 PM

The OVAL Phase 3 clinical trial evaluating VB-111 in platinum-resistant ovarian cancer has recruited more than 320 patients (>80 %) to date; Remains on track to complete enrollment in 1Q22 TEL AVIV, Israel,

VBLT

1 minute read

Vascular Biogenics Q2 EPS $(0.12) Misses $(0.11) Estimate, Sales $188.00K Miss $320.00K Estimate

By Luke J Jacobi

Today, 5:11 PM

Vascular Biogenics (NASDAQ:VBLT) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 14.29 percent increase over losses of $(0.14) per share

VBLT

8 minute read

Earnings Scheduled For August 16, 2021

By Benzinga Insights

Today, 5:11 PM

Companies Reporting Before The Bell • Entera Bio (NASDAQ:ENTX) is likely to report earnings for its second quarter. • Data Storage (NASDAQ:DTST) is expected to report earnings for its second quarter.

ACRX